{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:37:10Z","timestamp":1786736230119,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Perspect Clin Res"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/picr.picr_140_18","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T02:22:35Z","timestamp":1580437355000},"page":"24","source":"Crossref","is-referenced-by-count":17,"title":["Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006\u20132017"],"prefix":"10.4103","volume":"11","author":[{"given":"Viswam","family":"Subeesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reddy","family":"Neha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Beulah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nair","family":"Gouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eswaran","family":"Maheswari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-3485.257228-1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.idc.2009.01.008","article-title":"Meta-analyses on pediatric infections and vaccines","author":"Grammatikos","year":"2009","journal-title":"Infect Dis Clin North Am"},{"key":"key-10.4103\/2229-3485.257228-2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1525-1497.2003.20130.x","article-title":"Adverse drug event monitoring at the food and drug administration","author":"Ahmad","year":"2003","journal-title":"J Gen Intern Med"},{"key":"key-10.4103\/2229-3485.257228-3","doi-asserted-by":"crossref","unstructured":"Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. Pharmacoepidemiology. 3rd ed. John Wiley & Sons, Ltd; 2000. p. 149-74.","DOI":"10.1002\/0470842555.ch10"},{"key":"key-10.4103\/2229-3485.257228-4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.605","article-title":"Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: Novel functions of E6 and E7 oncoproteins","author":"Yugawa","year":"2009","journal-title":"Rev Med Virol"},{"key":"key-10.4103\/2229-3485.257228-5","doi-asserted-by":"crossref","unstructured":"papillomavirus infection. Am J Med 1997;102:3-8.","DOI":"10.1016\/S0002-9343(97)00177-0"},{"key":"key-10.4103\/2229-3485.257228-6","unstructured":"World Health Organization. Human Papillomavirus (HPV) and Cervical Cancer. World Health Organization; 2016."},{"key":"key-10.4103\/2229-3485.257228-7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2005.09.011","article-title":"Impact of HPV infection in adolescent populations","author":"Moscicki","year":"2005","journal-title":"J Adolesc Health"},{"key":"key-10.4103\/2229-3485.257228-8","first-page":"300","article-title":", Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.4103\/2229-3485.257228-9","unstructured":"Food and Drug Administration. GARDASIL\u00ae Quadrivalent Package Inserts. Food and Drug Administration; 2006."},{"key":"key-10.4103\/2229-3485.257228-10","unstructured":"Food and Drug Administration. CERVARIX Bivalent Package Inserts. Food and Drug Administration; 2009."},{"key":"key-10.4103\/2229-3485.257228-11","unstructured":"Food and Drug Administration. GARDASIL\u00ae 9 \u2013 Package Insert. Food and Drug Administration; 2014."},{"key":"key-10.4103\/2229-3485.257228-12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1503\/cmaj.080916","article-title":"Anaphylaxis following quadrivalent human papillomavirus vaccination","author":"Brotherton","year":"2008","journal-title":"CMAJ"},{"key":"key-10.4103\/2229-3485.257228-13","doi-asserted-by":"crossref","first-page":"a2642","DOI":"10.1136\/bmj.a2642","article-title":"Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: Retrospective cohort study","author":"Kang","year":"2008","journal-title":"BMJ"},{"key":"key-10.4103\/2229-3485.257228-14","first-page":"2","article-title":"Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental","author":"Tomljenovic","year":"2012","journal-title":"Pharm Regul Aff S"},{"key":"key-10.4103\/2229-3485.257228-15","first-page":"457","article-title":"Syncope after vaccination \u2013 United states, January 2005-July 2007","author":"Centers","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.4103\/2229-3485.257228-16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12026-016-8815-9","article-title":"Quadrivalent human papillomavirus vaccine and autoimmune adverse events: A case-control assessment of the vaccine adverse event reporting system (VAERS) database","author":"Geier","year":"2017","journal-title":"Immunol Res"},{"key":"key-10.4103\/2229-3485.257228-17","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1212\/WNL.0b013e3181aa53bb","article-title":"Acute disseminated encephalomyelitis following vaccination against human papillomavirus","author":"Wildemann","year":"2009","journal-title":"Neurology"},{"key":"key-10.4103\/2229-3485.257228-18","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1016\/j.vaccine.2008.06.074","article-title":"Brachial plexus neuritis following HPV vaccination","author":"Debeer","year":"2008","journal-title":"Vaccine"},{"key":"key-10.4103\/2229-3485.257228-19","first-page":"222","article-title":"Bilateral papilledema following human papillomavirus vaccination","author":"Rossi","year":"2011","journal-title":"J Med Cases"},{"key":"key-10.4103\/2229-3485.257228-20","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1592\/phco.28.9.1194","article-title":"Development of unilateral cervical and supraclavicular lymphadenopathy after human papillomavirus vaccination","author":"Studdiford","year":"2008","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/2229-3485.257228-21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"key-10.4103\/2229-3485.257228-22","unstructured":"VAERS [Internet]. Vaccine Adverse Event Reporting System (VAERS). Available from: https:\/\/vaers.hhs.gov\/about.html. [Cited 2017 Oct 08]."},{"key":"key-10.4103\/2229-3485.257228-23","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"key-10.4103\/2229-3485.257228-24","unstructured":"U.S. Code of Federal Regulations. 21CFR312.32 Postmarketing Reporting of Adverse Experiences; 2017."},{"key":"key-10.4103\/2229-3485.257228-25","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). Data Mining Applications in Engineering and Medicine. InTech; 2012.","DOI":"10.5772\/50095"},{"key":"key-10.4103\/2229-3485.257228-26","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2015.05.006","article-title":"Vaccination errors reported to the vaccine adverse event reporting system, (VAERS) United States, 2000-2013","author":"Hibbs","year":"2015","journal-title":"Vaccine"},{"key":"key-10.4103\/2229-3485.257228-27","first-page":"1","article-title":"General recommendations on immunization.Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP)","author":"Atkinson","year":"2002","journal-title":"MMWR Recomm Rep"},{"key":"key-10.4103\/2229-3485.257228-28","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/87.18.1365","article-title":"Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia","author":"Ho","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/2229-3485.257228-29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"key-10.4103\/2229-3485.257228-30","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-barr\u00e9 syndrome","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-3485.257228-31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4161\/hv.26292","article-title":"Guillain-barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the united states","author":"Ojha","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.4103\/2229-3485.257228-32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajp.2017.09.005","article-title":"Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database","author":"Subeesh","year":"2017","journal-title":"Asian J Psychiatr"},{"key":"key-10.4103\/2229-3485.257228-33","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","author":"Chen","year":"1994","journal-title":"Vaccine"},{"key":"key-10.4103\/2229-3485.257228-34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pds.1107","article-title":"Comparing data mining methods on the VAERS database","author":"Banks","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:39:12Z","timestamp":1786732752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.PICR_140_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["257228"],"URL":"https:\/\/doi.org\/10.4103\/picr.picr_140_18","relation":{},"ISSN":["2229-3485"],"issn-type":[{"value":"2229-3485","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}